ES2183815T3 - Quimioterapia para el cancer. - Google Patents

Quimioterapia para el cancer.

Info

Publication number
ES2183815T3
ES2183815T3 ES93918397T ES93918397T ES2183815T3 ES 2183815 T3 ES2183815 T3 ES 2183815T3 ES 93918397 T ES93918397 T ES 93918397T ES 93918397 T ES93918397 T ES 93918397T ES 2183815 T3 ES2183815 T3 ES 2183815T3
Authority
ES
Spain
Prior art keywords
fatty acid
fas
cells
acid synthesis
chemotherapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93918397T
Other languages
English (en)
Inventor
Francis P Kuhajda
Gary R Pasternack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Application granted granted Critical
Publication of ES2183815T3 publication Critical patent/ES2183815T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

LA SINTESIS DE ACIDOS GRASOS (FAS) ESTA SOBRE-EXPRESADA EN CARCINOMAS CON PRONOSTICO POBRE, PERO POCO DE LA EXPRESION FAS SE IDENTIFICA CON TEJIDOS NORMALES. LA INHIBICION DE LA SINTESIS DE ACIDOS GRASOS ES SELECTIVAMENTE TOXICA PARA CELULAS DE CARCINOMA, MIENTRAS LAS CELULAS NORMALES CON UNA ACTIVIDAD FAS PEQUEÑA SON RESISTENTES. ESTA INVENCION PROPORCIONA UN METODO DE TRATAMIENTO PARA LOS PACIENTES DE CANCER DONDE LA SINTESIS DE ACIDOS GRASOS POR CELULAS DE LOS TUMORES DE PACIENTES SE INHIBEN CON LA RESULTANTE INTERRUPCION DEL PROCESO DE LA ENFERMEDAD.
ES93918397T 1992-07-24 1993-07-26 Quimioterapia para el cancer. Expired - Lifetime ES2183815T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91771692A 1992-07-24 1992-07-24

Publications (1)

Publication Number Publication Date
ES2183815T3 true ES2183815T3 (es) 2003-04-01

Family

ID=25439227

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93918397T Expired - Lifetime ES2183815T3 (es) 1992-07-24 1993-07-26 Quimioterapia para el cancer.

Country Status (12)

Country Link
EP (1) EP0651636B1 (es)
JP (1) JPH07509470A (es)
KR (2) KR100329245B1 (es)
AT (1) ATE225167T1 (es)
AU (1) AU682007B2 (es)
CA (1) CA2140866C (es)
DE (1) DE69332353T2 (es)
DK (1) DK0651636T3 (es)
ES (1) ES2183815T3 (es)
MX (1) MX9304501A (es)
PT (1) PT651636E (es)
WO (1) WO1994002108A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614551A (en) * 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents
US5607967A (en) * 1994-10-27 1997-03-04 Merck & Co., Inc. Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid
AU7668596A (en) * 1995-11-17 1997-06-11 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
US6875451B2 (en) 1997-10-15 2005-04-05 Polarx Biopharmaceuticals Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
PL343868A1 (en) * 1997-11-10 2001-09-10 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
CN1233476A (zh) 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
ATE330598T1 (de) * 1999-11-12 2006-07-15 Univ Johns Hopkins Behandlung von krebs durch erhöhung des malonyl- coa-spiegels
US7427689B2 (en) 2000-07-28 2008-09-23 Georgetown University ErbB-2 selective small molecule kinase inhibitors
US20020173447A1 (en) * 2001-02-15 2002-11-21 Pizer Ellen Sarah Cytostatic effects of fatty acid synthase inhibition
US7432304B2 (en) 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
AU2002360335A1 (en) 2001-11-01 2003-05-12 The Regents Of The University Of Michigan Small molecule inhibitors targeted at bcl-2
MXPA05004390A (es) * 2002-10-31 2005-11-23 Fasgen Llc Metodo para inhibicion del desarrollo del cancer por inhibidores de la sintasa de acidos grasos.
JP5172146B2 (ja) * 2003-05-09 2013-03-27 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 癌を標的化するための組成物及び方法
US7342046B2 (en) 2004-03-25 2008-03-11 The Regents Of The University Of Michigan Gossypol co-crystals and the use thereof
WO2006020403A2 (en) * 2004-07-28 2006-02-23 Board Of Regents, The University Of Texas System 3-halo-2-oxopropionate salts and esters as novel anticancer agents
WO2007117038A1 (ja) * 2006-04-07 2007-10-18 Japanese Foundation For Cancer Research 癌の予防・治療剤
US8729239B2 (en) 2009-04-09 2014-05-20 Nuclea Biotechnologies, Inc. Antibodies against fatty acid synthase
EP2993980B1 (en) * 2013-05-10 2023-11-01 Memorial Sloan Kettering Cancer Center Lipid scavenging in ras cancers
KR102136643B1 (ko) 2018-12-04 2020-07-22 재단법인대구경북과학기술원 신규한 간암 진단 마커 및 이의 용도
JP7376330B2 (ja) * 2019-11-25 2023-11-08 花王株式会社 分岐脂肪酸の代謝制御方法
TW202133727A (zh) * 2019-11-25 2021-09-16 日商花王股份有限公司 分枝脂肪酸之代謝控制方法
JP7376331B2 (ja) * 2019-11-25 2023-11-08 花王株式会社 分岐脂肪酸の代謝制御方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328246A (en) * 1979-08-14 1982-05-04 Joseph Gold Anti Walker 256 carcinoma agent and combination thereof
JPS59225115A (ja) * 1983-06-06 1984-12-18 Ota Seiyaku Kk 青魚類から得た長鎖高度不飽和脂肪酸を含有する微細カプセル
JPS6058917A (ja) * 1983-09-09 1985-04-05 Rikagaku Kenkyusho 制癌剤
GB8607137D0 (en) * 1986-03-21 1986-04-30 Efamol Ltd Compositions
DD252616B1 (de) * 1986-09-08 1990-06-20 Adw Ddr Verfahren zur herstellung von cerulenin auf mikrobiologischem wege
JPH01132542A (ja) * 1987-11-19 1989-05-25 Toomen:Kk ゴッシポールラセミ体の光学分割法
JPH02113850A (ja) * 1988-10-21 1990-04-26 Nippon Oil & Fats Co Ltd 発癌抑制用油脂組成物
JPH02247125A (ja) * 1989-03-17 1990-10-02 Koken Kk 悪性腫瘍細胞増殖抑制剤

Also Published As

Publication number Publication date
CA2140866C (en) 2003-05-27
JPH07509470A (ja) 1995-10-19
DE69332353T2 (de) 2003-07-10
WO1994002108A1 (en) 1994-02-03
MX9304501A (es) 1994-04-29
PT651636E (pt) 2003-02-28
AU4786493A (en) 1994-02-14
KR100329245B1 (ko) 2002-03-18
EP0651636A1 (en) 1995-05-10
DE69332353D1 (de) 2002-11-07
KR100325766B1 (ko) 2002-07-27
ATE225167T1 (de) 2002-10-15
CA2140866A1 (en) 1994-02-03
DK0651636T3 (da) 2003-01-27
EP0651636B1 (en) 2002-10-02
AU682007B2 (en) 1997-09-18

Similar Documents

Publication Publication Date Title
ES2183815T3 (es) Quimioterapia para el cancer.
DK0738107T3 (da) Inhibitorer for fedtsyresyntese som antimikrobielle midler
HUP0000558A2 (hu) Aktív D-vitamin analógok alkalmazása prosztatabetegségek kezelésére szolgáló gyógyszerkészítmények előállítására
DE69713526D1 (de) Lösliche prodrugs von paclitaxel
BG103152A (en) Appoptosis-inducing adamantyl derivatives and their application as anticarcerogenic forms
MX9804009A (es) Inhibicion de crecimiento tumoral por oligonucleotidos de antisentido para il-8 y receptor de il-8.
AU1195499A (en) Thyroxine analogues having no significant hormonal activity to treat malignant tumors
IL127384A0 (en) Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
PL323798A1 (en) Application of derivatives of vitamin d4 in treating skin diseases
CA2337205A1 (en) Treatment of skin disorders
JP2714402B2 (ja) 癌転移抑制剤
BRPI0414736A (pt) 5-aril-pirimidinas como agentes anticáncer
WO2002039999B1 (en) Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition
WILLETT et al. Adjuvant postoperative radiation therapy for colonic carcinoma
BR9808263A (pt) Processos para tratar câncer em um humano em necessidade de tratamento e para manufaturar um medicamento para inibir o crescimento em um humano de um tumor sólido, e, uso de um composto.
Rubin et al. Phase II Study of PALA in Advanced Large Bowel Carcinoma 1, 2
US5525626A (en) Treating susceptible human malignant tumors with 7-hydroxy-1,2-benzopyrone
RU2000101293A (ru) Производные бензо(5,6)циклогепта(1,2-в)пиридина для ингибирования фарнезил-протеин-трансферазы
KR920700636A (ko) 인체의 악성 종양을 치료하기 위한 1,2-벤조피론 유도체의 용도
Pendl et al. Intracranial melanomas
JP3718533B2 (ja) ジヒドロキシフェニルスルフィド誘導体またはその塩を含む抗メラノーマ剤
Kröger et al. 361 Dexverapamil to overcome anthracycline-resistance in advanced breast cancer
Berson et al. 852 Adjuvant radiation therapy for soft tissue sarcomas of the extremities
Fentiman Long-term follow-up of the first breast conservation trial (Guy's Wide Excision Study)
Garcia-Giralt et al. Treatment of stage D hormone resistant carcinoma of the prostate with adriamycin, VM26, cyclophosphamide & 5 FU associated with des